Compare Stocks: QTTB, REPL, OMER, and ALMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$9.90 +1.0%	$23.99	$3.76 ▼ $31.35	$1.27B	-0.81	3.44 million shs	4.73 million shs
OMER Omeros	$18.59 -4.1%	$14.27	$3.94 ▼ $19.65	$1.40B	2.6	2.23 million shs	1.23 million shs
QTTB Q32 Bio	$10.72 -3.8%	$14.90	$1.69 ▼ $23.57	$331.63M	0.21	391,613 shs	937,620 shs
REPL Replimune Group	$13.24 -8.4%	$12.50	$1.50 ▼ $16.33	$1.36B	0.94	2.21 million shs	3.64 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.37%	-5.31%	-64.40%	-53.18%	+129.51%
OMER Omeros	+1.41%	+2.81%	+42.36%	+90.47%	+355.16%
QTTB Q32 Bio	-4.70%	-18.03%	-28.91%	-12.28%	+525.84%
REPL Replimune Group	-2.17%	-9.57%	+5.71%	+67.63%	+148.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$9.90 +1.0%	$23.99	$3.76 ▼ $31.35	$1.27B	-0.81	3.44 million shs	4.73 million shs
OMER Omeros	$18.59 -4.1%	$14.27	$3.94 ▼ $19.65	$1.40B	2.6	2.23 million shs	1.23 million shs
QTTB Q32 Bio	$10.72 -3.8%	$14.90	$1.69 ▼ $23.57	$331.63M	0.21	391,613 shs	937,620 shs
REPL Replimune Group	$13.24 -8.4%	$12.50	$1.50 ▼ $16.33	$1.36B	0.94	2.21 million shs	3.64 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-7.37%	-5.31%	-64.40%	-53.18%	+129.51%
OMER Omeros	+1.41%	+2.81%	+42.36%	+90.47%	+355.16%
QTTB Q32 Bio	-4.70%	-18.03%	-28.91%	-12.28%	+525.84%
REPL Replimune Group	-2.17%	-9.57%	+5.71%	+67.63%	+148.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$33.27	236.09% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	104.41% Upside
QTTB Q32 Bio	2.86	Moderate Buy	$31.00	189.18% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-9.37% Downside

Current Analyst Ratings Breakdown

Latest QTTB, REPL, OMER, and ALMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	QTTB Q32 Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
9/1/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/1/2026	ALMS Alumis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/26/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $21.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	53.28	N/A	N/A	$2.88 per share	3.44
OMER Omeros	N/A	N/A	$1.79 per share	10.36	($1.71) per share	N/A
QTTB Q32 Bio	$53.74M	5.94	$1.46 per share	7.35	$3.41 per share	3.14
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.52	16.45	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	3.57	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)

Latest QTTB, REPL, OMER, and ALMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
OMER Omeros	N/A	1.95	1.94
QTTB Q32 Bio	N/A	20.30	20.30
REPL Replimune Group	1.00	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
OMER Omeros	48.79%
QTTB Q32 Bio	31.32%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
OMER Omeros	10.50%
QTTB Q32 Bio	34.46%
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	129.43 million	85.82 million	N/A
OMER Omeros	210	72.39 million	64.79 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A
REPL Replimune Group	210	93.80 million	88.73 million	Optionable

QTTB, REPL, OMER, and ALMS Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Shares Down 6.9% - Here's Why

September 10 at 1:59 PM | marketbeat.com

REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact SueWallSt

September 10 at 10:09 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

September 10 at 10:00 AM | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 9 at 1:00 PM | newsfilecorp.comN

REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

September 9 at 10:07 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 8 at 5:36 PM | globenewswire.com

REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

September 8 at 10:11 AM | globenewswire.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 8 at 9:39 AM | globenewswire.com

Bank of New York Mellon Corp Takes $2.61 Million Position in Replimune Group, Inc. $REPL

September 8 at 3:36 AM | marketbeat.com

Readystate Asset Management LP Purchases 161,470 Shares of Replimune Group, Inc. $REPL

September 7 at 5:36 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 4, 2026 | globenewswire.com

Replimune Group (NASDAQ:REPL) Sets New 1-Year High - Here's Why

September 4, 2026 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.3% - Should You Sell?

September 3, 2026 | marketbeat.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 3, 2026 | globenewswire.com

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 3, 2026 | globenewswire.com

REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

September 3, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

September 3, 2026 | prnewswire.com

Replimune to Present at the Cantor Global Healthcare Conference 2026

September 3, 2026 | globenewswire.com

Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.

September 2, 2026 | tmcnet.com

Replimune Group (NASDAQ:REPL) Reaches New 1-Year High - Here's Why

September 2, 2026 | marketbeat.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

September 2, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

QTTB, REPL, OMER, and ALMS Company Descriptions

Alumis NASDAQ:ALMS

$9.90 +0.10 (+1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$9.91 +0.01 (+0.14%)

As of 07:58 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Omeros NASDAQ:OMER

$18.59 -0.80 (-4.13%)

Closing price 04:00 PM Eastern

Extended Trading

$18.52 -0.07 (-0.39%)

As of 07:57 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Q32 Bio NASDAQ:QTTB

$10.72 -0.42 (-3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$10.73 +0.01 (+0.09%)

As of 07:47 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Replimune Group NASDAQ:REPL

$13.24 -1.21 (-8.37%)

Closing price 04:00 PM Eastern

Extended Trading

$13.34 +0.10 (+0.72%)

As of 07:52 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, REPL, OMER, and ALMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, REPL, OMER, and ALMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, REPL, OMER, and ALMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QTTB, REPL, OMER, and ALMS Company Descriptions

Alumis NASDAQ:ALMS

Omeros NASDAQ:OMER

Q32 Bio NASDAQ:QTTB

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, REPL, OMER, and ALMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, REPL, OMER, and ALMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, REPL, OMER, and ALMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QTTB, REPL, OMER, and ALMS Company Descriptions

Alumis NASDAQ:ALMS

Omeros NASDAQ:OMER

Q32 Bio NASDAQ:QTTB

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools